BamSEC and AlphaSense Join Forces
Learn More

Jasper Therapeutics Inc.

NASDAQ: JSPR    
Share price (12/20/24): $21.57    
Market cap (12/20/24): $324 million

Material Contracts Filter

EX-10.6
from 8-K 13 pages Amended and Restated Employment Agreement
12/34/56
EX-10.5
from 8-K 13 pages Amended and Restated Employment Agreement
12/34/56
EX-10.4
from 8-K 13 pages Amended and Restated Employment Agreement
12/34/56
EX-10.3
from 8-K 13 pages Amended and Restated Employment Agreement
12/34/56
EX-10.36
from 10-K 3 pages 1. Position: I Am Pleased to Offer You the Position of Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) and Corporate Secretary With the Company. You Will Report to Ron Martell, CEO & President. This Is a Full-Time Position, and You Will Be Required to Devote Your Full Professional Attention to Your Work at the Company. It Is Anticipated That Your Management Team Will Outline and Collaborate With You Regarding the Individual Goals You Are Expected to Achieve. the Company Reserves the Right to Change Your Position, Duties, Work Location, Reporting Relationship and Compensation From Time to Time in Its Discretion. 2. Start Date: It’s Anticipated That Your Start Date Will Be September 22, 2023. if There Is a Need to Change the Start Date, We Will Identify Another Mutually Acceptable Date for You and the Company. a Change in Start Date Does Not Change the Remaining Terms of This Offer Letter
12/34/56
EX-10.35
from 10-K 3 pages 1. Position: I Am Pleased to Offer You the Position of Chief Medical Officer With the Company. You Will Report to Ron Martell, CEO & President. This Is a Full-Time Position, and You Will Be Required to Devote Your Full Professional Attention to Your Work at the Company. It Is Anticipated That Your Management Team Will Outline and Collaborate With You Regarding the Individual Goals You Are Expected to Achieve. 2. Start Date: It’s Anticipated That Your Start Date Will Be June 12, 2023. if There Is a Need to Change the Start Date, We Will Identify Another Mutually Acceptable Date for You and the Company. a Change in Start Date Does Not Change the Remaining Terms of This Offer Letter
12/34/56
EX-10.2
from 10-Q 2 pages Amendment № 1 to the Exclusive License Agreement Effective the 25th Day of March 2021 Between Stanford University and Jasper Therapeutics, Inc
12/34/56
EX-10.1
from 8-K 14 pages Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 3 pages First Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 1 page April 13, 2023 William Lis Delivered via Email: Blis@jaspertherapeutics.com Re: Service Agreement - Chairperson of the Board and Consulting Services Jasper Therapeutics, Inc. Signed: /S/ Ronald Martell Name: Ronald Martell Title: CEO and Director Accepted and Agreed: /S/ William Lis William Lis Date: April 13, 2023
12/34/56
EX-10.17
from 10-K 4 pages Jasper Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 10-Q 31 pages Jasper Therapeutics, Inc. Shares of Voting Common Stock (Par Value $0.0001 Per Share) Controlled Equity Offeringsm Sales Agreement
12/34/56
EX-10.6
from 10-Q 10 pages Confidential Separation Agreement and General Release of All Claims
12/34/56
EX-10.7
from S-8 5 pages Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.6
from S-8 7 pages Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan Stock Option Agreement
12/34/56
EX-10.1
from 8-K 13 pages Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 5 pages March 7, 2022 William Lis Delivered via Email Re: Service Agreement - Chairperson of the Board and Consulting Services
12/34/56
EX-10.1
from 8-K 12 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 4 pages Jasper Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.14
from 8-K 3 pages Amendment to Sponsor Support Agreement
12/34/56